Adolescent Exercise Linked to Reduced Risk of Cancer, Cardiovascular Disease
the Cancer Therapy Advisor take:
Adolescent exercise was found to be associated with a decreased risk of death caused by cancer, cardiovascular disease (CVD), and all causes, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
This study included 74,941 Chinese women (40-70 years) who took part in the Shanghai Women’s Health Study (SWHS) between 1996 and 2000.
Results showed adolescent exercise for less than or equal to 1.33 hours per week hazard ratios (HR, 0.83; 95% CI, 0.72, 0.95); (HR, 0.83; 95% CI, 0.70, 0.98); and (HR, 0.78; 95% CI, 0.71, 0.85) and greater than 1.33 hours per week (HR, 0.83; 95% CI, 0.74, 0.93); (HR, 0.62; 95% CI, 0.53, 0.72); and (HR, 0.71; 95% CI, 0.66, 0.77) were both associated with reduced mortality risk caused by cancer, CVD, and all causes, HRs reported, respectively.
Furthermore, an inverse association was observed between participation in sports teams and cancer mortality (HR, 0.86; 95% CI: 0.76, 0.97).
After adjusting for adult and adolescent factors, the authors concluded joint adolescent and adult exercise was also linked to reduced risk of cancer, CVD, and all-cause mortality (HR, 0.87; 95% CI, 0.74, 1.01), (HR, 0.83; 95% CI, 0.69, 1.00), and (HR, 0.80; 95% CI, 0.72, 0.89), respectively, and found exercise during adolescence was inversely related to cancer mortality (HR, 0.84; 95% CI: 0.71, 0.98).
Adolescent exercise was found to be associated with a decreased risk of death caused by cancer, cardiovascular disease.
Adolescent exercise was found to be associated with a decreased risk of death caused by cancer, cardiovascular disease (CVD), and all causes, according to an article published online in the journalCancer Epidemiology, Biomarkers & Prevention.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Calcium and Cancer
- Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths
- NSCLC: Genetic Mutations May Determine Likelihood of Metastasis at Diagnosis
- CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective
- Atezolizumab Monotherapy Effective in PD-L1 Non-small Cell Lung Cancer
- Platinum Therapy Should Not Be Delayed in Ovarian Cancer Relapse
- Identifying Frail Patients With Multiple Myeloma Improves Treatment Selection
- Outcomes in Pancreatic Cancer Not Improved by Gemcitabine Plus Erlotinib
- Cabozantinib Effective as Salvage Therapy in Thyroid Cancer
- Q&A With Kristian Thidemann Andersen, MD, PhD: Infection in Multiple Myeloma After HDT-ASCT